Urine Alkalinisation to Prevent AKI in COVID-19

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim is to explore the feasibility and safety of urine alkalinisation in critically ill patients with COVID-19.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guy's and St Thomas' NHS Foundation Trust

Criteria

Inclusion Criteria:

• Confirmed Covid-19 positive

• Admission to Critical Care Unit

• Bladder catheter in situ

• Central line in place (including PICC line)

• Age ≥18y

• Written informed consent to participate in the study

Exclusion Criteria:

• Stage 3 AKI (as defined by KDIGO criteria)

• Chronic kidney disease stage 4 or 5

• Contraindications to NaHCO3 therapy (e.g. risk of serious drug interaction, systemic metabolic alkalosis, congestive heart failure)

• Urine pH > 7.0

• Serum sodium >150mmol/L

• Blood pressure >180/100mgHg

• Severe hypokalaemia (K<3.0mmol/L)

• Inability to grant informed consent

• Severe hypocalcaemia (Cai <0.8 mmol/L)

• Pregnant or lactating and breast-feeding women

• Unwilling to use contraception

• Patient is on a medication that may interact with sodium bicarbonate